|
Kamada Ltd is a biopharmaceutical company developing, producing and marketing a line of specialty, life-saving therapeutics using its proprietary chromatographic purification technology.
Highlights
1991: Kamada was founded in Israel and by 1998, was manufacturing 10 products in 15 countries.
2004: Kamada received Orphan Drug Designation for inhaled AAT(Alpha-1 Antitrypsin) by the FDA and EMEA. AAT became Kamada's flagship product for the treatment of various lung disorders.
2005: Kamada became Israel's first public biopharmaceutical company.
2006: A strategic agreement was reached with Germany's PARI Pharma to develop inhalation for AAT.
2007: Kamada was granted a US patent for Transferrin; Intravenous AAT Phase III clinical trials began in the US; EMEA approved
inhaled AAT Phase-II-III clinical plans and FDA approval was granted for KamRab, an anti-rabies immune drug's Phase II-III clinical plans.
2008: Kamada received a European patent for its AAT Manufacturing Process. Kamada and PARI entered a new licensing agreement to use PARIs eFlow electronic drug nebulizer with additional indications for Kamada's AAT drug. Aerosolized AAT successfully completed Phase II clinical trials for the treatment of cystic fibrosis and bronchiectasis.
2009: A new laboratory was established in Beit-Kama, Israel
2010: Kamada's intravenous AAT product, Glassia™ (Baxter International), is the only available emphysema treatment available in a stable, ready-to-use liquid form. It is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
2011: The FDA approved orphan drug status give Kamada the exclusive right to sell the drug for seven years in the US, pending full drug approval.
2012: D1-AAT with AAT, which treats Type 1 diabetes received a positive interim report on the preliminary results of a Phase 1/11 clinical trial, the first time the drug was administered to children.
Returns and Investments
2008: Kamada entered into a $4 million private equity investment agreement with Shavit Capital Fund. Kamada signed a $20M financing agreement with US based Hercules Technology Growth Capital, Inc.
2010: Revenue rose 65% over the NIS 128.7 million revenue in 2010.
2011:Kamada Ltd. (TASE: KMDA) predicts NIS 257 million ($69 million) revenue in 2012, after posting NIS 212.8 million ($59 million) revenue in 2011, beating its own predictions of NIS 195 million.
*Pictures courtesy of Kamada
|